Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | TLR4 | O00206 | 10/20 | 0.53 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.49 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.49 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.49 |
| ▸ | CHIA | Q9BZP6 | 1/20 | 0.47 |
| ▸ | CD69 | Q07108 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | LY96 | Q9Y6Y9 | 6/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20685510 | 1.00 | MAPK1 (0.54) | MAPK1TLR4LGALS3LGALS8LGALS4 | |
| SCHEMBL25924370 | 1.00 | MAPK1 (0.54) | MAPK1TLR4LGALS3LGALS8LGALS4 | |
| SCHEMBL16502193 | 1.00 | MAPK1 (0.54) | MAPK1TLR4LGALS3LGALS8LGALS4 | |
| SCHEMBL16433864 | 1.00 | MAPK1 (0.54) | MAPK1TLR4LGALS3LGALS8LGALS4 | |
| SCHEMBL16623686 | 1.00 | MAPK1 (0.54) | MAPK1TLR4LGALS3LGALS8LGALS4 | |
| SCHEMBL16623992 | 1.00 | MAPK1 (0.54) | MAPK1TLR4LGALS3LGALS8LGALS4 | |
| SCHEMBL18024461 | 1.00 | MAPK1 (0.54) | MAPK1TLR4LGALS3LGALS8LGALS4 | |
| SCHEMBL16502194 | 0.95 | MAPK1 (0.60) | MAPK1TLR4LGALS3LGALS8LGALS4 | |
| SCHEMBL19225396 | 0.94 | MAPK1 (0.55) | MAPK1TLR4LGALS3LGALS8LGALS4 | |
| SCHEMBL24955827 | 0.94 | MAPK1 (0.58) | MAPK1TLR4LGALS3LGALS8LGALS4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210037831-A1 | Stable Inoculant Compositions and Methods for Producing Same | NOVOZYMES BIOAG A/S (DK) | 2021-02-11 | — | — | US | disclosed |
| US-20200154716-A1 | STABLE LIQUID INOCULANT COMPOSITIONS COMPRISING DODECANE | NOVOZYMES BIOAG A/S (DK) | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210037831-A1 | Stable Inoculant Compositions and Methods for Producing Same | SPOUT1, ERG28, EXOSC9 | MAPK1 4029/4885TLR4 1973/4885LGALS3 2703/4885 |
| US-20200154716-A1 | STABLE LIQUID INOCULANT COMPOSITIONS COMPRISING DODECANE | SPOUT1, HDHD5, DAD1 | MAPK1 4000/4885TLR4 329/4885LGALS3 1505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.